RxDoctor Payments Data

Jason Everman, DO

Family Medicine · Indianapolis, INNPI 1881866572

Payments from drug & device makers

$3,198in general payments, 2019–2025

Across 172 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$804
  • Lilly USA, LLC$442
  • AbbVie$422
  • Pfizer$143
  • Amgen$142
  • Radius Health, Inc.$114
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$3,186100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,198 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$59,919
Medicare patients
151
Services billed
908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$180,608
MounjaroTirzepatide116$135,654
EliquisApixaban69$90,105
Humira(Cf) PenAdalimumab12$82,241
JardianceEmpagliflozin26$40,475
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$40,449
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen815$29,420
JanuviaSitagliptin Phosphate18$27,899
Spiriva RespimatTiotropium Bromide36$25,854
LinzessLinaclotide24$22,112
TrulicityDulaglutide18$20,778
Spiriva HandihalerTiotropium Bromide19$20,699
Breo ElliptaFluticasone/Vilanterol38$20,150
OxycontinOxycodone Hcl13$19,754
FarxigaDapagliflozin Propanediol15$19,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$804$180,608142 claims
Lilly USA, LLCMounjaro, Trulicity$442$156,432134 claims
PfizerEliquis, Premarin$143$105,66587 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Shingrix$99$94,528151 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$48$82,82186 claims
AstraZenecaFarxiga, Brilinta$93$30,90832 claims
AbbVieLinzess$422$22,11224 claims
Astellas Pharma US IncMyrbetriq$96$16,06919 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$50$12,95815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →